Navigation Links
Vaccine for Ebola virus
Date:3/30/2008

One of the worlds deadliest diseases, caused by the Ebola virus, may finally be preventable thanks to US and Canadian researchers, who have successfully tested several Ebola vaccines in primates and are now looking to adapt them for human use.

Dr Anthony Sanchez, from the Centers for Disease Control & Prevention in Atlanta, Georgia is presenting an overview of Ebola vaccine development today (Monday 31 March 2008) at the Society for General Microbiologys 162nd meeting being held this week at the Edinburgh International Conference Centre.

The biothreat posed by Ebola virus cannot be overlooked. We are seeing more and more naturally occurring human outbreaks of this deadly disease. With worldwide air travel and tourism the virus can now be transported to and from remote regions of the world. And it has huge potential as a possible weapon of bioterrorism, says Dr Sanchez. We desperately need a protective vaccine.

So far, there have been over 1500 cases of Ebola haemorrhagic fever in humans. Illness starts abruptly and symptoms include fever, headache, sore throat, weakness, joint and muscle aches, diarrhoea, vomiting and stomach pain. A rash, red eyes and bleeding may also occur. Ebola haemorrhagic fever can have a mortality rate of around 90% in humans.

Because Ebola virus is so dangerous, producing and testing a vaccine is extremely challenging for the scientists. One significant factor slowing down progress has been that there are only a very limited number of high containment facilities with staff capable and authorised to conduct the research.

Ebola virus is a Biosafety Level 4 threat, along with many other haemorrhagic fever viruses, says Dr Sanchez. As well as the difficulty in getting the right staff and facilities, vaccines for viruses like Ebola, Marburg and Lassa fever have been difficult to produce because simple killed viruses that just trigger an antibody response from the blood are not effective. For the
'/>"/>

Contact: Lucy Goodchild
l.goodchild@sgm.ac.uk
44-011-898-81843
Society for General Microbiology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Iowa State researchers look for smaller, cheaper, 1-dose vaccines
2. HIV isolate from Kenya provides clues for vaccine design
3. CWRU School of Medicine has evidence vaccine against malaria will reduce disease
4. Penn researchers find monkeys able to fend off AIDS-like symptoms with enhanced HIV vaccine
5. An Alzheimers vaccine?
6. Influenza vaccine causes weaker immune response for children of rural Gabon than in semi-urban areas
7. Flu vaccine in painless skin patches under development at Emory, Georgia Tech with NIH grants
8. New nanoparticle vaccine is more effective but less expensive
9. Study by Pittsburgh researchers identifies possible vaccine target for chlamydia
10. Possible hepatitis C vaccine
11. Ebola virus disarmed by excising a single gene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... fatty acids and energy to infants and children ... that soybean-based emulsions could compromise immune functions and ... lipid emulsions based on triglyceride oil, fish oil, ... this concern. , However, researchers at Rutgers and ... according to a review published today in the ...
(Date:7/22/2014)... consists of both still images and video of ... research. Forty-four still images were chosen from more ... staff, and alumni representing more than 25 different ... than 50 submissions. , Zach Donnell, a graduate ... 2014 organizers, noted that the exhibit highlights the ...
(Date:7/22/2014)... BEDFORD, Mass., July 22, 2014 Aware, Inc. (NASDAQ: ... and services, today reported financial results for its second quarter ... quarter of 2014 was $6.8 million, an increase of 53% ... Operating income before patent related income in the second quarter ... the second quarter of 2013. The increase in revenue and ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... be taken during radiation therapy treatments because they ... normal prostate cell lines, leading to normal tissue ... issue of the International Journal of Radiation ... Society for Radiation Oncology (ASTRO). Many prostate cancer ...
... The Society for Nutrition Education (SNE) has ... American Society for Nutrition (ASN) to publish a ... American Society for Nutrition, and Society for Nutrition ... Adults," focusing on access to safe and adequate ...
... This release is available in Spanish . ... found in South America that can cause terrible, Ebola-like ... Now, Howard Hughes Medical Institute (HHMI) researchers ... hemorrhagic fever virus latches onto and infects human cells, ...
Cached Biology News:Dietary supplements discouraged for prostate cancer patients 2Nutrition services for older adults at home and in communities 2New ways to disarm deadly South American hemorrhagic fever viruses 2New ways to disarm deadly South American hemorrhagic fever viruses 3
(Date:7/23/2014)... DuPont Pioneer announced today that Neal Gutterson, ... Agricultural Biotechnology (ABT), effective July 21, 2014. Gutterson joins ... as president, chief executive officer and board member. , ... seed and crop protection industry to this integral role ... president of DuPont Pioneer. “I am looking forward to ...
(Date:7/23/2014)... , July 23, 2014 /PRNewswire/ - BioAmber Inc. ... company producing sustainable chemicals, today announced that the underwriters ... their option to purchase an additional 420,000 shares ... of $12.00 per share, less underwriting discounts and ... public offering of 2,800,000 shares of common stock, ...
(Date:7/23/2014)... BRUSSELS , July 23, 2014 regulated ... its research and development pipeline with positive topline ... brivaracetam . This study was designed to evaluate ... (100 and 200 mg/day, without titration) compared to ... patients with partial-onset seizures, not fully controlled despite ...
(Date:7/23/2014)... , July 23, 2014 ... SHPG ), the global specialty biopharmaceutical company, and ... announced a worldwide licensing and collaboration agreement for ... the potential treatment of both the central nervous ... Hunter syndrome (MPS II). This collaboration strengthens Shire,s ...
Breaking Biology Technology:DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5
... 8 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a ... affordable vaccines based on proprietary manufacturing technologies and ... been awarded a proof of concept contract by ... laboratory specifically the Edgewood Chemical Biological Center ("ECBC") ...
... Guacamole is a little prettier in October as your ... "Pink" Guacamole. Nielsen-ranked, top-selling Wholly Guacamole, is for the ... proceeds from October "PINK" sales to help fight for ... of Texas-Based Wholly,s support for National Breast Cancer Awareness ...
... ... ... October 8, 2009 -- iCardiac Technologies, Inc., a global leader in advanced cardiac core ... iCardiac a comprehensive cardiac safety study. iCardiac will provide end-to-end study management, equipment ...
Cached Biology Technology:Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy 2Grocery Produce Fighting for a Cause - Wholly 'Pink' Guacamole 2Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 2
Mouse monoclonal antibody to CDC2L5 - cell division cycle 2-like 5 (cholinesterase-related cell division controller)...
...
Our Histology, Immunohistochemistry and tissue arrays services include samples processing, different type of staning, histollogical stains, image analysis, tissue arrays, immunohistochemistry, etc....
Mouse monoclonal antibody to PDK2 - pyruvate dehydrogenase kinase, isoenzyme 2...
Biology Products: